Dr. Mian founded Curelator Inc. in 2013 based on the belief that one-size-fits-all medicine was failing the majority of humans who were not “average”. This short-coming is most acutely observed in chronic diseases with episodic attacks such as migraine, IBS, epilepsy, depression where medications are therapeutically effective in only a minority of patients.
The solution was to develop the first digital health platform using N=1 analytics to enable personalized measurement of therapeutic response and identification of disease modifying life-style factors. The Company’s first product is N1-Headache, which is indicated for migraine and is being used in multiple clinical studies.
Previously, Dr. Mian was CEO and a co-founder of Genmedica Therapeutics SL, a biotechnology company founded in 2005 in Barcelona, Spain to develop therapeutics for metabolic diseases such as type 2 diabetes. Under Dr. Mian’s leadership, Genmedica developed one of the few novel approaches for developing drugs that target disease pathogenesis rather than just symptoms. Using this approach Genmedica became one of Spain’s leading biotechnology startups, closing Spain’s largest life-science financing round in 2012. Genmedica’s compounds are currently in phase II clinical trials.
Before that, Dr. Mian was CEO and co-founder of Gamera Biosciences Corporation in Boston, USA which was founded in 1993 to develop high-speed, microfluidics technology for the drug discovery and genomics industries. The company was financed by local and international venture capital sources. In 1999 Gamera was sold to Tecan Ltd (SWX: TECN), a publicly-traded Swiss biomedical company.
Dr. Mian completed his Bachelors in biology at McGill University in Montreal, Canada. He completed his doctorate in genetics at University of Cambridge, UK, with Dr. Gabriel Dover; and Harvard Medical School, Boston, USA, with Dr. George Church. He is author or co-author of dozens patents and publications. Dr. Mian is a citizen of Germany and Canada.